Eli Lilly and Company (NYSE ... LillyDirect digital healthcare platform to offer connections to independent in-person and telehealth options for people in the U.S. living with Alzheimer's disease ...

Drugmaker Eli Lilly and Company has hired Sandy Rodriguez as SVP and chief communications officer, effective on June 9. Rodriguez will report to Jennifer Oleksiw, SVP and global chief customer officer ...

Eli Lilly’s weight loss drug Zepbound outperformed ... An important implication, for instance, is that if a person doesn’t respond well or experiences intolerable side effects with one weight ...

Eli Lilly, Johnson & Johnson Innovation, the Myeloma Investment Fund and Tachyon Ventures. The 40-person company is led by CEO Emile Nuwaysir, Ph.D., former CEO of Bayer’s cell therapy outfit ...

(Bloomberg) -- Eli Lilly & Co.’s obesity drug Zepbound helped ... so doctors recommend that a person’s waistline be no more than half their height. “If you have more abdominal fat, you ...

A new film from Eli Lilly sounds like a recruitment ad ... as a "medicine company" with humanity at its core: "At Lilly, we see a person on the other side of the prescription," Polimeni said.

Eli Lilly (NYSE: LLY) has been a growth beast over the years and is now easily the most valuable healthcare company in the ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Now, let's return to our question: Should you invest $1,000 in Lilly right now? The shares are trading for 34 times forward earnings estimates -- that's around the same level as top tech companies ...

The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly's (NYSE: LLY) Zepbound delivering ...

Eli Lilly (NYSE: LLY) is one of the undisputed leaders in developing anti-obesity medicines, with Novo Nordisk (NYSE: NVO) being its biggest challenger. Over the past six months, Eli Lilly has ...